GlassScriptPhysician profile
Renu Bhatia
NPI 1093817058
$1,917.33
in general payments reported to CMS, 2019-2025
14 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $188 · 2022: $611 · 2023: $389 · 2024: $251 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $857.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $385.53 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Abbvie INC. | $335.01 | 2022-2024 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $332.08 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $259.37 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $143.89 | 2023 | Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.91 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $90.88 | 2022 | |
| Lundbeck LLC | $87.56 | 2020-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $45.58 | 2020-2022 | |
| Allergan, INC. | $41.24 | 2019-2020 | |
| Axsome Therapeutics, INC. | $21.81 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $15.41 | 2019 | |
| Amarin Pharma, INC. | $14.56 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renu Bhatia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.